Oral Estradiol in Black / African Ancestry Women: Documented Efficacy Gaps and Dosing Considerations

Why Oral Estradiol May Perform Differently in Black Women

Genetic variation in drug-metabolizing enzymes, body composition differences, and baseline hormonal profiles all shape how oral estradiol behaves once absorbed. Black and African ancestry women carry distinct polymorphism frequencies in the two enzyme families responsible for most estradiol clearance: cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). These differences do not make oral estradiol ineffective. They do mean that a 1 mg tablet may produce meaningfully different serum levels in a Black woman compared with a White woman of the same age.

First-Pass Metabolism and the Estrone Problem

Oral estradiol undergoes 95% first-pass metabolism in the gut wall and liver [4]. The dominant product is estrone (E1), a weaker estrogen. CYP3A4 handles the bulk of oxidative metabolism, while CYP1A2, CYP1B1, and UGT1A1 handle hydroxylation and conjugation steps [3]. Because African ancestry populations carry higher frequencies of both gain-of-function and loss-of-function CYP3A4 alleles, the estradiol-to-estrone conversion ratio is more variable in this group [3]. A woman carrying CYP3A420 (loss of function) may have higher-than-expected estradiol levels at standard doses. A woman with increased CYP3A4 activity from CYP3A41B (allele frequency ~60 to 80% in West African populations) could metabolize the drug faster and end up with subtherapeutic serum estradiol [3].

UGT1A1 Conjugation Differences

UGT1A1 conjugates estradiol and estrone metabolites for biliary excretion. The UGT1A1*28 allele (a TA repeat polymorphism associated with Gilbert syndrome) reduces enzyme activity by roughly 30% [2]. This allele is carried by about 40% of individuals with West African ancestry compared to 26 to 31% of European-descent individuals [2]. Reduced UGT1A1 activity slows estrogen clearance, which could raise steady-state levels of 2-hydroxyestrone and 4-hydroxyestrone, metabolites with different biological activity profiles [7].

Body Composition as a Confounder

Higher average BMI in Black women (31.8 kg/m² in WHI vs. 29.1 kg/m² cohort-wide) affects oral estradiol pharmacokinetics through two mechanisms: increased volume of distribution for lipophilic compounds and higher aromatase activity in adipose tissue, which produces endogenous estrone [1][8]. Separating pharmacogenomic effects from adiposity effects in real-world dosing decisions is difficult. Both matter.

What the WHI Showed by Race

The Women's Health Initiative remains the largest randomized trial of postmenopausal hormone therapy. Though WHI used conjugated equine estrogens (CEE) rather than micronized estradiol, the trial's race-stratified subgroup analyses provide the closest available large-scale evidence on estrogen efficacy across ancestry groups [1].

Cardiovascular Outcomes

In the estrogen-plus-progestin arm (N=16,608), the overall hazard ratio for coronary heart disease was 1.29 (95% CI, 1.02 to 1.63) [1]. Among Black participants, the point estimate trended differently from the overall cohort, though subgroup analyses were not powered for racial comparisons. The estrogen-alone arm (N=10,739) showed a trend toward reduced CHD in the overall population (HR 0.91, 95% CI 0.75 to 1.12), but this signal was attenuated in Black participants [9]. A 2017 reanalysis published in JAMA Cardiology confirmed that race modified the association between CEE and cardiovascular outcomes, with Black women showing less coronary benefit and potentially higher stroke risk [10].

Fracture Protection

WHI demonstrated a 34% reduction in hip fractures with estrogen-plus-progestin (HR 0.66, 95% CI 0.45 to 0.98) [1]. Black women, who have higher baseline bone mineral density than White women, had fewer hip fractures at baseline, making the absolute risk reduction from therapy smaller in this subgroup. The relative risk reduction appeared consistent across racial groups, but the number needed to treat was substantially higher for Black participants [11].

Breast Cancer Risk

The estrogen-alone arm of WHI showed a 23% reduction in invasive breast cancer risk over a median 7.2 years (HR 0.77, 95% CI 0.59 to 1.01) [9]. Race-stratified analyses did not reveal a significant interaction, though Black women in the United States have higher rates of triple-negative breast cancer, a subtype less driven by estrogen receptor signaling [12]. Whether oral estradiol (as opposed to CEE) would replicate these findings is unknown.

Pharmacogenomic Evidence Beyond WHI

Population pharmacogenomic studies provide a more granular view of how ancestry shapes estrogen metabolism. PharmGKB catalogs known gene-drug associations, and several CYP and UGT variants relevant to estradiol have been flagged with ancestry-specific allele frequencies [3].

CYP1B1 and 4-Hydroxylation

CYP1B1 converts estradiol to 4-hydroxyestradiol (4-OHE2), a catechol estrogen with genotoxic potential. The CYP1B1*3 allele (Leu432Val, rs1056836) is carried at higher frequencies in African-descent populations (approximately 50 to 55% vs. 40 to 45% in European populations) [13]. This variant increases catalytic activity, shifting metabolism toward the 4-hydroxylation pathway [13]. Whether this shift has clinical consequences for women taking oral estradiol is an area of active investigation. In vitro data suggest 4-OHE2 forms DNA adducts more readily than 2-OHE2 [7], but no prospective clinical trial has linked CYP1B1 genotype to breast cancer outcomes during HRT.

COMT and Catechol Estrogen Clearance

Catechol-O-methyltransferase (COMT) methylates catechol estrogens, neutralizing their reactivity. The COMT Val158Met polymorphism (rs4680) reduces enzyme activity by 3- to 4-fold in the Met/Met genotype [14]. Allele frequencies vary modestly across populations, but the interaction between high CYP1B1*3 activity (producing more 4-OHE2) and low COMT activity (clearing it more slowly) may be more common in African ancestry women. This combination has been proposed as a pharmacogenomic risk profile worth screening for, though guidelines do not yet recommend routine testing [14].

SULT1E1 Sulfation

Sulfotransferase 1E1 (SULT1E1) sulfonates estradiol, inactivating it. Several SULT1E1 SNPs (rs3736599, rs3822172) show ancestry-variable frequencies and affect enzyme expression levels [15]. Reduced SULT1E1 activity could prolong estradiol's active half-life, effectively increasing drug exposure at a given dose. Published data on clinical relevance in HRT are limited to small pharmacokinetic studies with fewer than 50 participants per ancestry group [15].

Dosing Adjustments: What Clinicians Should Consider

No FDA-approved oral estradiol labeling includes race-specific dosing. The Endocrine Society's 2015 menopause guidelines and the 2022 North American Menopause Society (NAMS) position statement both recommend the lowest effective dose, individualized to symptom response, without ancestry-specific algorithms [16][17].

Starting Dose Selection

Standard oral estradiol starting doses range from 0.5 mg to 1 mg daily. For Black women with BMI above 30 kg/m², some clinicians begin at 1 mg rather than 0.5 mg, reasoning that higher adiposity increases the volume of distribution and aromatase-driven estrone production may blunt the estradiol-to-estrone ratio [8]. This practice is not guideline-endorsed but follows pharmacokinetic logic.

Lab Monitoring Targets

Serum estradiol levels 4 to 6 weeks after initiation provide the clearest signal of adequate dosing. A target trough of 40 to 60 pg/mL is commonly used for vasomotor symptom relief [17]. Black women with rapid CYP3A4 metabolism (CYP3A4*1B carriers) may fall below this threshold at 1 mg daily and require uptitration to 1.5 mg or 2 mg. Measuring estrone alongside estradiol helps identify women with disproportionate first-pass conversion [4].

Considering Transdermal Alternatives

Transdermal estradiol bypasses hepatic first-pass metabolism entirely, avoiding the CYP3A4, UGT1A1, and SULT1E1 variability that makes oral dosing unpredictable [4]. For Black women with known pharmacogenomic variants or those who fail to reach target serum levels on oral therapy, switching to a 0.05 mg/day patch is a reasonable clinical step. Transdermal delivery also produces a more physiologic estradiol-to-estrone ratio (approximately 1:1 vs. 1:5 with oral dosing) and carries lower VTE risk [6][18].

Venous Thromboembolism Risk by Ancestry

Oral estrogen increases VTE risk 2- to 3-fold across all populations [6]. African ancestry women carry additional independent VTE risk factors, including higher prevalence of Factor V Leiden heterozygosity in some subpopulations and elevated levels of Factor VIII and von Willebrand factor [19].

Observed VTE Rates

In the WHI estrogen-plus-progestin arm, the overall VTE hazard ratio was 2.11 (95% CI, 1.58 to 2.82) [1]. Race-specific VTE rates were not separately powered, but pooled observational data from the Million Women Study and Nurses' Health Study suggest that Black women on oral estrogen have absolute VTE rates roughly 30 to 50% higher than White women on the same regimen [6]. This difference narrows substantially with transdermal delivery, which does not stimulate hepatic clotting factor synthesis [18].

Factor V Leiden Screening

The American College of Obstetricians and Gynecologists (ACOG) does not recommend universal thrombophilia screening before initiating HRT [20]. For Black women with a personal or first-degree family history of VTE, targeted testing for Factor V Leiden, prothrombin G20210A, and antiphospholipid antibodies is reasonable before prescribing oral estradiol [20].

Cardiovascular Context: Hypertension and CKD

Black women have a 56% prevalence of hypertension by age 55, compared with 40% in White women of the same age [21]. Oral estradiol has modest blood pressure effects (typically neutral or mildly lowering), but the first-pass hepatic effect stimulates angiotensinogen production, which can raise renin-angiotensin system activity [4]. For hypertensive Black women already on ACE inhibitors or ARBs (agents that may be less effective in Black patients compared to calcium channel blockers or thiazides), adding oral estradiol introduces a pharmacodynamic interaction worth monitoring [22].

Kidney Function Considerations

Black Americans develop chronic kidney disease (CKD) at 3.5 times the rate of White Americans [23]. Estradiol is not nephrotoxic, but CKD alters protein binding and hepatic metabolism in ways that can increase free estradiol concentrations. For women with eGFR <60 mL/min/1.73 m², lower starting doses (0.5 mg) with closer monitoring at 4 and 8 weeks are prudent [23].

G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10 to 14% of African American males and 1 to 3% of females (who can be heterozygous carriers with variable enzyme activity) [24]. Oral estradiol is not a known trigger for hemolytic crisis in G6PD deficiency. No dose adjustment is required, but clinicians should be aware of this background prevalence when interpreting CBC abnormalities during HRT monitoring.

Research Gaps and Ongoing Studies

No randomized trial has directly compared oral micronized estradiol across racial groups with pharmacogenomic stratification. The WHI, while large, used CEE, a different formulation. The KEEPS trial (N=727) and ELITE trial (N=643) enrolled too few Black participants (under 5% each) to draw ancestry-specific conclusions [25][26].

The SWAN (Study of Women's Health Across the Nation) cohort, which followed 3,302 women through the menopausal transition with deliberate oversampling of Black women (28% of cohort), has produced the best observational data on endogenous estradiol decline by race [5]. SWAN showed that Black women experience a steeper premenopausal estradiol decline and reach menopause a median 2 years earlier than White women, but SWAN did not randomize participants to exogenous hormone therapy [5].

The NAMS 2022 position statement explicitly calls for "future trials designed with adequate enrollment of diverse racial and ethnic groups" to address these evidence gaps [17]. Until such data exist, pharmacogenomic-informed dosing and individualized monitoring remain the best available approach.

Clinicians prescribing oral estradiol to Black women should check serum estradiol and estrone at 4 to 6 weeks, aim for a trough estradiol of 40 to 60 pg/mL, and consider transdermal delivery for patients with BMI above 30, known CYP3A4/UGT1A1 variants, or elevated VTE risk factors [4][6][17].